Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that belongs to the proprotein convertase family. PCSK9 is synthesized as a zymogen and its prodomain is cleaved by its own catalytic activity. The cleaved prodomain forms a protein complex with the rest of the PCSK9 carboxyl terminus within the endoplasmic reticulum and is secreted. Secreted PCSK9 has been shown to be able to reduce low-density lipoprotein receptor (LDLR) levels in vitro and in vivo. Thus PCSK9 has emerged as an important player modulating LDLR levels and plasma LDL cholesterol. Furthermore, PCSK9 deficiency leads to significantly lowered LDL cholesterol levels in humans and provides dramatic protection against coronary heart disease. We review here the current understanding of PCSK9 and its potential as a therapeutic target through which to reduce LDL cholesterol for prevention and treatment of coronary heart disease.
Keywords: PCSK9, LDL cholesterol, LDL receptor, endocytosis, proprotein convertase
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
Volume: 8 Issue: 4
Author(s): Guoqing Cao, Yue-Wei Qian, Mark C. Kowala and Robert J. Konrad
Affiliation:
Keywords: PCSK9, LDL cholesterol, LDL receptor, endocytosis, proprotein convertase
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that belongs to the proprotein convertase family. PCSK9 is synthesized as a zymogen and its prodomain is cleaved by its own catalytic activity. The cleaved prodomain forms a protein complex with the rest of the PCSK9 carboxyl terminus within the endoplasmic reticulum and is secreted. Secreted PCSK9 has been shown to be able to reduce low-density lipoprotein receptor (LDLR) levels in vitro and in vivo. Thus PCSK9 has emerged as an important player modulating LDLR levels and plasma LDL cholesterol. Furthermore, PCSK9 deficiency leads to significantly lowered LDL cholesterol levels in humans and provides dramatic protection against coronary heart disease. We review here the current understanding of PCSK9 and its potential as a therapeutic target through which to reduce LDL cholesterol for prevention and treatment of coronary heart disease.
Export Options
About this article
Cite this article as:
Cao Guoqing, Qian Yue-Wei, Kowala C. Mark and Konrad J. Robert, Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187153008786848286
DOI https://dx.doi.org/10.2174/187153008786848286 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience New Strategies in Treatment of Mineral and Bone Disorders and Associated Cardiovascular Disease in Patients with Chronic Kidney Disease
Recent Patents on Cardiovascular Drug Discovery Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Investigation on Risk Factor of Vascular Thrombotic Diseases in Patients with Obstructive Sleep Apnea Hypopnea Syndrome
Vascular Disease Prevention (Discontinued) Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Editorial [Hot Topic Intracellular Calcium Signaling: Holding the Balance between Health and Disease Guest Editor: Luca Munaron]
Current Medicinal Chemistry What Restricts the Clinical Use of Nicotinic Acid?
Current Vascular Pharmacology Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Current Vascular Pharmacology Recent Patents on Hypocholesterolemic Therapeutic Strategies: An Update
Recent Advances in DNA & Gene Sequences (Discontinued) Long-Chain Omega-3 Fatty Acid Deficiency in Mood Disorders: Rationale for Treatment and Prevention
Current Drug Discovery Technologies Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Current Clinical Pharmacology Hedgehog Signaling and Urological Cancers
Current Drug Targets Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Application of Nanomedicine in Cardiovascular Diseases and Stroke
Current Pharmaceutical Design Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH
Current Vascular Pharmacology